Alexander Gold Sells 6,933 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Director Alexander Gold sold 6,933 shares of the business’s stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $46.72, for a total value of $323,909.76. The transaction was disclosed in a legal filing with the SEC, which is available at this link.

Mineralys Therapeutics Price Performance

NASDAQ MLYS opened at $40.85 on Friday. The stock’s 50 day simple moving average is $40.17 and its 200-day simple moving average is $23.97. The company has a market cap of $3.23 billion, a PE ratio of -13.85 and a beta of 0.40. Mineralys Therapeutics, Inc. has a 1-year low of $8.24 and a 1-year high of $47.65.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings results on Monday, November 10th. The company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.66) by $0.14. On average, equities research analysts anticipate that Mineralys Therapeutics, Inc. will post -4.23 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on the stock. The Goldman Sachs Group increased their target price on shares of Mineralys Therapeutics from $32.00 to $52.00 and gave the company a “buy” rating in a research report on Tuesday, September 9th. Jefferies Financial Group increased their price objective on shares of Mineralys Therapeutics from $15.00 to $26.00 and gave the company a “hold” rating in a report on Wednesday, September 3rd. HC Wainwright increased their price target on Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday. Wells Fargo & Company lifted their price objective on Mineralys Therapeutics from $50.00 to $55.00 and gave the stock an “overweight” rating in a research report on Tuesday. Finally, Wall Street Zen raised Mineralys Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, August 22nd. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $46.67.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. increased its stake in Mineralys Therapeutics by 26.7% during the first quarter. RA Capital Management L.P. now owns 6,147,280 shares of the company’s stock worth $97,619,000 after acquiring an additional 1,296,296 shares during the last quarter. SR One Capital Management LP lifted its stake in shares of Mineralys Therapeutics by 55.1% in the 1st quarter. SR One Capital Management LP now owns 3,127,933 shares of the company’s stock valued at $49,672,000 after purchasing an additional 1,111,111 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Mineralys Therapeutics by 29.8% during the 3rd quarter. Vanguard Group Inc. now owns 3,018,999 shares of the company’s stock worth $114,480,000 after purchasing an additional 692,550 shares during the period. Caligan Partners LP increased its position in shares of Mineralys Therapeutics by 37.4% during the 3rd quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock worth $105,139,000 after purchasing an additional 755,302 shares during the last quarter. Finally, Suvretta Capital Management LLC increased its position in shares of Mineralys Therapeutics by 22.2% during the 3rd quarter. Suvretta Capital Management LLC now owns 2,132,133 shares of the company’s stock worth $80,850,000 after purchasing an additional 387,641 shares during the last quarter. 84.46% of the stock is currently owned by hedge funds and other institutional investors.

About Mineralys Therapeutics

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone.